NCT01736878View on ClinicalTrials.gov

Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Medullary Thyroid Carcinoma

Interventions

DRUG

Sorafenib

Trial Locations (1)

D-89081

University Hospital Ulm, Clinic for Nuclear Medicine, Ulm

Sponsors

Lead Sponsor

Eanm Research Ltd

All Listed Sponsors

lead

Eanm Research Ltd

NETWORK